Recursion
AI-driven drug discovery platform using phenomics and massive biological datasets
Recursion is a serious techbio player with proprietary data, wet-lab automation, and clinical assets—but you can't buy it off the shelf. It's a partnership platform for deep-pocketed pharma, not a tool for small teams.
- Pharmaceutical companies seeking to accelerate early-stage drug discovery and reduce failure rates
- Biotech investors evaluating AI-driven pipelines with clinical assets
- Researchers in oncology and rare diseases looking for novel targets and molecules
- Partnerships requiring large-scale phenotypic data and AI modeling for drug development
- Startups or academic labs seeking a quick, low-cost AI tool for drug discovery (Recursion requires deep partnership)
- Teams focused solely on computational drug design without wet-lab validation (Recursion is heavily experimental)
- Companies needing a standalone software subscription (pricing is custom, not off-the-shelf)
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Recursion if you need a self-serve AI drug discovery tool or you are a small lab without resources for a deep partnership.
Partnership agreements may include milestone payments or royalties that are not transparent upfront.
Recursion uses custom partnership pricing—no public tiers. This fits large pharma and biotech with multi-million dollar R&D budgets. For smaller teams, cheaper alternatives like Insilico Medicine or Atomwise offer more accessible collaboration models.
In short
Recursion — AI-driven drug discovery platform using phenomics and massive biological datasets. Best for Pharmaceutical companies seeking to accelerate early-stage drug discovery and reduce failure rates, Biotech investors evaluating AI-driven pipelines with clinical assets, Researchers in oncology and rare diseases looking for novel targets and molecules. Contact Sales pricing.
Viability Score
How likely is Recursion to still be operational in 12 months? Based on 4 signals — momentum (how recently it shipped), wrapper dependency, revenue model, and web presence.
Last calculated: July 2026
How we score →Key Features
- Proprietary Recursion OS platform for drug discovery
- Automated wet lab generating millions of cell experiments per week
- Over 50 petabytes of biological and chemical data
- NVIDIA BioHive-2 supercomputer for AI model training
- Hit identification to IND-enabling studies with improved speed and cost
- Potential first-in-class treatments in oncology and rare diseases
- Advanced pipeline with phase 1/2/3 clinical trials (REC-4881, REC-3565)
- Target identification and validation using machine learning
- Generative AI for molecule design and optimization
- De-identified patient data integration for precision medicine
- Strategic partnerships with pharma and tech leaders
- End-to-end drug development capability from preclinical to pivotal studies
- Fit-for-purpose dataset generation including ADME and safety profiling
- Real-world evidence generation through clinical trials
- Continuous feedback loop from experiments into AI models
About Recursion
Recursion is an AI-driven drug discovery company that leverages its proprietary Recursion OS platform to decode biology and accelerate the development of new medicines. Founded over a decade ago on the novel approach of using cellular imaging and AI to understand disease biology, the company aims to reduce the 90% failure rate of traditional drug discovery. Its platform integrates massive biological and chemical datasets—over 50 petabytes of phenomics, transcriptomics, proteomics, ADME, and de-identified patient data—with an automated wet lab that captures millions of cell experiments per week. Recursion's pipeline includes potential first-in-class treatments for aggressive cancers and rare diseases, with several programs in clinical trials such as REC-4881 for advanced solid tumors (positive Phase 1b/2 results announced April 2025) and REC-3565 for B-cell lymphomas (first patient dosed October 2024). Strategic partnerships with pharmaceutical leaders and technology giants like NVIDIA (which built BioHive-2, biopharma's most powerful supercomputer) enable Recursion to rapidly identify novel targets and design optimized molecules. Unlike many AI drug discovery startups, Recursion has a robust pipeline and real-world validation through ongoing clinical trials, making it a credible alternative to conventional R&D.
Behind the Verdict
Recursion isn't a typical AI tool you can subscribe to—it's a full-stack drug discovery engine built for pharmaceutical partnerships. The platform's strength lies in its massive, fit-for-purpose datasets (>50 petabytes) and the feedback loop between automated wet-lab experiments and AI models. The clinical pipeline, including REC-4881 and REC-3565, gives it credibility that many AI-only startups lack. We'd consider Recursion if you're a large pharma company looking to de-risk early-stage discovery with real-world data and validated targets. But if you need a quick, off-the-shelf AI tool for molecule design or a software API, this isn't it. Compared to competitors like Insilico Medicine or Exscientia, Recursion's focus on phenomics (cellular imaging) rather than pure computational chemistry is a differentiator—but also a limitation for teams that don't have wet-lab capabilities. The pricing is custom and partnership-based, so don't expect a public price list. In practice, the biggest caveat is integration: you'll need to commit significant resources and timeline to collaborate. For startups or academic labs, better options might include smaller cloud-based platforms or open-source tools.
Researching Recursion? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Recursion actually fits — and what changes day-one when you adopt it.
You need to identify a novel target for an aggressive cancer pipeline.
Outcome: Recursion's platform screens millions of cell images, identifies a candidate target, and validates it in the automated wet lab within months—much faster than traditional approaches.
You evaluate AI drug discovery companies to invest in.
Outcome: Recursion's clinical pipeline (REC-4881, REC-3565) and massive proprietary dataset provide tangible validation, making it a credible investment target.
You want to explore a rare disease mechanism using phenomics.
Outcome: Through a partnership, Recursion runs high-content imaging experiments on your disease model and returns AI-predicted molecular candidates.
Use Cases
- Identify novel drug targets by analyzing phenomics data from cell imaging experiments.
- Design optimized preclinical molecules using generative AI models trained on proprietary datasets.
- Accelerate hit-to-lead and IND-enabling studies with automated wet lab validation.
- Partner with Recursion to co-develop treatments for oncology or rare diseases.
Models Under the Hood
as of 2026-07-05
Limitations
- Recursion does not offer a publicly accessible API or self-service platform; access requires a partnership or collaboration.
- Its automated wet labs are proprietary and not available for external use.
- The platform's complexity and scale mean it is unsuitable for small-scale or individual projects.
as of 2026-06-29
Where the pricing makes sense
The company stage and team size where Recursion's pricing actually pencils out — and where peers do it cheaper.
Recursion uses custom partnership pricing—no public tiers. This fits large pharma and biotech with multi-million dollar R&D budgets. For smaller teams, cheaper alternatives like Insilico Medicine or Atomwise offer more accessible collaboration models.
Setup time & first value
How long it actually takes to get something useful out of Recursion — broken out by persona, not the marketing-page minute.
For new partners, setup involves legal agreements, data integration, and alignment on project scope—typically 3-6 months before first experiments begin. Existing collaborators can start new projects within weeks.
Switching to or from Recursion
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From internal pharma R&D: Recursion acts as a complement, not a replacement; you submit targets or disease hypotheses for screening.
- →From traditional CROs: Recursion offers faster hit identification through its AI-wet lab loop, but requires data sharing.
- ↗To internal development: Recursion-identified candidates can be transferred to your own team for further development.
- ↗To another AI-driven CRO: If the partnership ends, you may retain data generated but lose access to Recursion's proprietary platform.
Integrations
Resources & Guides
Official links
Tools that pair well with Recursion
Common stack mates teams adopt alongside Recursion, with the specific reason each pairing earns its keep.
Alternatives to Recursion
View all
Nimbus Therapeutics
AI-driven small molecule drug discovery for selective oncology and immunology
Insilico Medicine
Generative AI drug discovery platform for pharma R&D
Frequently Asked Questions
Categories
Best-of guides
Used Recursion? Help shape our editorial sentiment research.